Compare EQBK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | GOSS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.8M | 796.2M |
| IPO Year | 2015 | 2019 |
| Metric | EQBK | GOSS |
|---|---|---|
| Price | $44.82 | $3.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $47.80 | $8.60 |
| AVG Volume (30 Days) | 75.3K | ★ 4.5M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $186,035,000.00 | $44,051,000.00 |
| Revenue This Year | $15.54 | N/A |
| Revenue Next Year | $37.88 | $6.41 |
| P/E Ratio | $44.72 | ★ N/A |
| Revenue Growth | ★ 17.93 | N/A |
| 52 Week Low | $34.11 | $0.76 |
| 52 Week High | $48.14 | $3.87 |
| Indicator | EQBK | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 45.93 |
| Support Level | $45.00 | $3.04 |
| Resistance Level | $45.71 | $3.87 |
| Average True Range (ATR) | 1.30 | 0.29 |
| MACD | -0.36 | -0.08 |
| Stochastic Oscillator | 11.98 | 11.45 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.